Skip to main content
. 2020 Apr 20;26(6):1421–1435. doi: 10.1007/s10741-020-09954-8

Table 1.

Baseline characteristics of included studies

Study NCT number Year Sponsor Active treatment Comparator Centres (n) Patients (n) Treatment duration (weeks)
Core period Extension period
Bailey [22] NCT00528879 2010 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 80 546 24 n.a.
Bailey [23] n.a. 2012 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 63 282 24 n.a.
Barnett [24] NCT01164501 2014 Boehringer Ingelheim, Eli Lilly Empagliflozin Placebo 127 738 52 n.a.
Bode [25] NCT01106651 2013 Janssen Research & Development, LLC Canagliflozin Placebo 90 716 26 n.a.
Bolinder [26, 27] NCT00855166 2012, 2014 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 40 182 24 78
Cefalu [28] NCT00968812 2013 Janssen Research & Development, LLC Canagliflozin Glimepiride 157 1450 52 n.a.
Cefalu [29] NCT01031680 2015 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 141 922 24 28
Dagogo-Jack [30] NCT02036515 2018 Merck & Co., Inc. Ertugliflozin Placebo 104 462 26 26
DeFronzo [31] NCT01422876 2015 Boehringer Ingelheim, Eli Lilly Empagliflozin Linagliptin 197 686 [413] 24 28
Ferdinand [32] NCT02182830 2019 Boehringer Ingelheim, Eli Lilly Empagliflozin Placebo 92 157 24 n.a.
Ferrannini [33] NCT00528372 2010 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 85 559 24 n.a.
Fioretto [34] NCT02413398 2018 AstraZeneca, National Institutes of Health Dapagliflozin Placebo 88 321 24 n.a.
Forst [35] NCT01106690 2014 Janssen Research & Development, LLC Canagliflozin Placebo 74 342 26 n.a.a
Frias [36], Jabbour [37] NCT02229396 2016, 2018 AstraZeneca Dapagliflozin Exenatide 134 694 [463] 28 25
Grunberger [38] NCT01986855 2018 Merck Sharp & Dohme Corp., Pfizer Inc. Ertugliflozin Placebo 121 467 52 n.a.
Hadjadj [39] NCT01719003 2016 Boehringer Ingelheim, Eli Lilly Empagliflozin Metformin 190 1364 [702] 24 n.a.
Haring [40] NCT01159600 2013 Boehringer Ingelheim Empagliflozin Placebo 148 669 24 n.a.
Haring [41] NCT01159600 2014 Boehringer Ingelheim Empagliflozin Placebo 148 637 24 n.a.
Henry [42] NCT00643851 2012 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Metformin 105 598 [404] 24 n.a.
Henry [42] NCT00859898 2012 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Metformin 131 638 [427] 24 n.a.
Hollander [43, 44] NCT01999218 2018 Merck & Co., Inc. Ertugliflozin Glimepiride 232 1325 52 52
Inagaki [45] NCT01413204 2014 Mitsubishi Tanabe Pharma Corporation Canagliflozin Placebo 5 272 24 n.a.
Jabbour [46] NCT00984867 2014 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 88 451 24 24
Ji [47] NCT01095653 2014 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 40 393 24 n.a.
Kadowaki [48] NCT02354235 2017 Mitsubishi Tanabe Pharma Corporation Canagliflozin Placebo 3 138 24 n.a.
Kaku [49] NCT01294423 2014 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 27 261 24 n.a.
Kohan [50] NCT00663260 2014 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 111 252 24 70
Kovacs [51, 52] NCT01210001 2014, 2015 Boehringer Ingelheim Empagliflozin Placebo 69 498 24 52
Lavalle-Gonzalez [53] NCT01106677 2013 Janssen Research & Development, LLC Canagliflozin Placebo 169 1284 26 n.a.
Leiter [54] NCT01042977 2014 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 173 965 24 28
Lewin [55] NCT01422876 2015 Boehringer Ingelheim, Eli Lilly Empagliflozin Linagliptin 197 677 [405] 52 n.a.
Mathieu [56, 57] NCT01646320 2015, 2016 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 67 320 24 26
Matthaei [58] NCT01392677 2015 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 46 218 24 n.a.
Müller-Wieland [59] NCT02471404 2018 AstraZeneca Dapagliflozin Glimepiride 194 939 [627] 52 n.a.
Nauck [60] NCT00660907 2011 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Glipizide 95 814 52 n.a.
Neal [4] NCT01032629, NCT01989754 2017 Janssen Research & Development, LLC Canagliflozin Placebo 667 10,142 188 n.a.
Perkovic [61] NCT02065791 2019 Janssen Research & Development, LLC Canagliflozin Placebo 690 4397 136 n.a.
Phrommintikul [62] NCT03178591 2019 Thailand Research Fund, National Science and Technology Development Agency NSTDA Dapagliflozin Vildagliptin 1 49 24 n.a.
Pollock [63] NCT02547935 2019 AstraZeneca Dapagliflozin Placebo 116 448 [296] 24 n.a.
Pratley [64] NCT02099110 2018 Merck & Co., Inc., Pfizer Inc. Ertugliflozin Sitagliptin 21 1232 [745] 52 n.a.
Ridderstrale [65, 66] NCT01167881 2014, 2018 Boehringer Ingelheim, Eli Lilly Empagliflozin Glimepiride 173 1545 104 104
Rodbard [67] NCT02025907 2013 Janssen Research & Development, LLC Canagliflozin Placebo 47 216 26 n.a.
Roden [68, 69] NCT01177813, NCT01289990 2013, 2015 Boehringer Ingelheim, Eli Lilly Empagliflozin Sitagliptin, placebo 124 899 24 52
Rosenstock [70] NCT00683878 2012 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 105 420 48 n.a.
Rosenstock [71] NCT01606007 2015 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Saxagliptin 139 534 [355] 24 n.a.
Rosenstock [72] NCT01011868 2015 Boehringer Ingelheim, Eli Lilly Empagliflozin Placebo 97 494 78 n.a.
Rosenstock [73] NCT01809327 2016 Janssen Research & Development, LLC Canagliflozin Metformin 158 1186 [712] 26 n.a.
Rosenstock [74] NCT02033889 2018 Merck Sharp & Dohme Corp., Pfizer Ertugliflozin Placebo ? 621 26 n.a.a
Schernthaner [75] NCT01137812 2013 Janssen Research & Development, LLC Canagliflozin Sitagliptin 140 755 52 n.a.
Scott [76] NCT02532855 2018 Merck & Co., Inc. Dapagliflozin Sitagliptin 185 614 24 n.a.
Softeland [77] NCT01734785 2017 Boehringer Ingelheim, Eli Lilly Empagliflozin Placebo 90 332 24 n.a.
Stenlof [78] NCT01081834 2013 Janssen Research & Development, LLC Canagliflozin Placebo 79 584 26 n.a.a
Strojek [79, 80] NCT00680745 2011, 2014 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 84 596 24 24
Terra [81] NCT01958671 2017 Pfizer, Inc., Merck & Co., Inc. Ertugliflozin Placebo 67 461 26 n.a. a
Wilding [82, 83] NCT00673231 2012, 2014 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 126 807 24 80
Wilding [84] NCT01106625 2013 Janssen Research & Development, LLC Canagliflozin Placebo 85 469 26 26
Wiviott [5] NCT01730534 2019 AstraZeneca Dapagliflozin Placebo 882 17,160 218 n.a.
Yale [85] NCT01064414 2013 Janssen Research & Development, LLC Canagliflozin Placebo 89 269 26 n.a.
Yang [86] NCT01095666 2016 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 32 444 24 n.a.
Yang [87] NCT02096705 2018 AstraZeneca Dapagliflozin Placebo 28 272 24 n.a.
Zinman [6] NCT01131676 2015 Boehringer Ingelheim, Eli Lilly Empagliflozin Placebo 590 7020 164 n.a.
AstraZeneca NCT00736879 Bristol-Myers Squibb, AstraZeneca Dapagliflozin Placebo 62 282 24 n.a.
AstraZeneca NCT02681094 AstraZeneca Dapagliflozin Saxagliptin 119 883 [590] 24 n.a.
Merck Sharp & Dohme Corp. NCT02630706 Merck Sharp & Dohme Corp., Pfizer Ertugliflozin Placebo 50 506 26 n.a.

aDuring the extension period of the trial, patients on placebo or active control changed their treatment. Therefore, only the core period of the respective trial was considered for analyses. n.a., not available. Numbers in brackets show the number of patients available for endpoint analyses (if different to the total number of patients included in the respective trial)